12:00 AM
Apr 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DCR-MYC: Phase I started

Dicerna began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV DCR-MYC, with a starting dose of 0.1 mg/kg, given on days 1, 8 and 15...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >